Retrophin to Report Third Quarter 2020 Financial Results
21. Oktober 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the...
Retrophin to Present at Upcoming Investor Conferences
03. August 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following upcoming virtual investor conferences in August:...
Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
19. Juni 2020 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success...
Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results
24. Februar 2020 16:01 ET
|
Retrophin, Inc.
Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings Full year 2019 net product sales of $175 million SAN DIEGO, Feb. 24,...
Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN
22. August 2019 06:00 ET
|
Retrophin, Inc.
FORT Study did not achieve its primary or secondary endpoints Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc....
Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference
31. Juli 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth...
Retrophin to Report Second Quarter 2019 Financial Results
23. Juli 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, July 23, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the...
Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
28. Juni 2019 16:34 ET
|
Retrophin, Inc.
Enteric-coated formulation offers flexible dosing options, including administration with or without food THIOLA EC expected to be available to patients next month SAN DIEGO, June 28, 2019 (GLOBE...
Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome
18. Juni 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, June 18, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the...
Retrophin to Present at Upcoming Investor Conferences
30. Mai 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in June: Jefferies...